US Patent 8,653,119: Tafamidis Meglumine Patent Scope, Expiration, Orange Book Status, and Generic Risk

US Patent 8,653,119 protects methods of treating transthyretin amyloid disease with a pharmaceutically acceptable salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, particularly the N-methyl-D-glucamine salt known as tafamidis meglumine. The patent is a method-of-use patent, not a broad composition-of-matter patent covering all tafamidis forms.

The patent’s principal commercial relevance is Vyndaqel, Pfizer’s tafamidis meglumine product. Its claims are directed to treatment of transthyretin amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, and cardiac amyloidosis after liver transplantation.[1]

The patent’s projected expiration is June 7, 2028, based on the patent record and applicable patent-term adjustment. The exact enforceable term remains subject to terminal disclaimers, patent-term adjustment, and any applicable regulatory patent-term extension.[2]

What drug does US Patent 8,653,119 protect?

US 8,653,119 covers therapeutic use of a tafamidis-related benzoxazole compound in salt form.

The relevant compound is:

Chemical name: 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Common active moiety: tafamidis
Claimed commercial salt: N-methyl-D-glucamine salt
Commercial product most directly associated with the claims: Vyndaqel
Product form: oral tafamidis meglumine capsules

The claims do not recite the word “tafamidis,” but the chemical name identifies tafamidis. The claims also do not cover every possible formulation or every use of the free-acid form of tafamidis. Their central limitation is administration of a pharmaceutically acceptable salt of the specified compound.

What are the independent claims in US 8,653,119?

The patent has two principal independent method claims.

Claim	Core subject matter	Main legal limitation
1	Treating transthyretin amyloid disease	Administering a therapeutically effective amount of a pharmaceutically acceptable salt of the specified benzoxazole
3	Treating transthyretin amyloid disease with a pharmaceutical composition	Administering a composition containing the salt and a pharmaceutically acceptable carrier

Claim 1 is directed to administration of the salt. Claim 3 adds a pharmaceutical-composition limitation requiring both the salt and a pharmaceutically acceptable carrier.

The two independent claims create overlapping but distinct infringement theories:

A product or treatment regimen involving administration of the salt may implicate claim 1.
A marketed dosage form containing the salt and an excipient or carrier may implicate claim 3.

The claims do not specify a particular capsule size, dose, dosing frequency, route, treatment duration, patient genotype, disease stage, biomarker, or clinical endpoint.

How do the dependent claims narrow the patent scope?

Claims 2 and 4 narrow the salt to the N-methyl-D-glucamine salt.

Claims 5 through 8 identify four transthyretin amyloid diseases:

Familial amyloid polyneuropathy
Familial amyloid cardiomyopathy
Senile systemic amyloidosis
Cardiac amyloidosis following liver transplantation

Claims 9 through 24 separately repeat those disease categories, with particular emphasis on familial amyloid cardiomyopathy, senile systemic amyloidosis, cardiac amyloidosis following liver transplantation, and familial amyloid polyneuropathy.

The claim structure is repetitive because it preserves separate combinations of:

Salt or composition
N-methyl-D-glucamine salt
Broad transthyretin amyloid disease
Specific disease subtype

This structure gives the patent multiple fallback positions if the broadest method claim is challenged. A narrower claim directed specifically to tafamidis meglumine and familial amyloid cardiomyopathy may remain relevant even if a broader claim is found unpatentable.

What disease indications are covered by US 8,653,119?

The patent expressly covers treatment of several forms of transthyretin amyloidosis.

Familial amyloid polyneuropathy

Familial amyloid polyneuropathy, also called hereditary transthyretin amyloid polyneuropathy, results from transthyretin mutations that cause amyloid deposition in peripheral nerves and other tissues.

Claims 21 through 24 expressly cover this disease, depending on whether the claim requires the broad salt, the N-methyl-D-glucamine salt, or the pharmaceutical composition.

Familial amyloid cardiomyopathy

Familial amyloid cardiomyopathy is associated with transthyretin variants that cause amyloid deposition in cardiac tissue. Claims 9 through 12 expressly cover this indication.

This disease category has the greatest commercial importance in the United States because the FDA approved tafamidis products for cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis.[3]

Senile systemic amyloidosis

Senile systemic amyloidosis, now commonly described as wild-type transthyretin amyloidosis, primarily affects older adults and frequently involves the heart.

Claims 13 through 16 expressly cover this disease.

Cardiac amyloidosis after liver transplantation

Claims 17 through 20 cover cardiac amyloidosis following liver transplantation. This language addresses continued or progressive disease after removal of the liver source of mutant transthyretin. It is a narrower disease setting than the broad cardiomyopathy claims.

What does US Patent 8,653,119 not clearly cover?

The patent does not expressly claim:

Tafamidis free acid as a standalone chemical composition
Every tafamidis formulation regardless of salt status
A specific dose or capsule strength
A particular treatment schedule
A loading dose or maintenance dose
A specific pharmacokinetic target
Combination treatment with an RNA-silencing product
Combination treatment with an antisense oligonucleotide
Manufacturing tafamidis or tafamidis meglumine
Crystalline polymorphs unless independently covered by another patent
A method limited to FDA-approved cardiomyopathy labeling

The distinction between tafamidis meglumine and tafamidis free acid is commercially important. Vyndaqel contains tafamidis meglumine, while Vyndamax contains tafamidis in the free-acid form. The patent claims expressly identify a pharmaceutically acceptable salt, with the dependent claims specifically identifying the meglumine salt.[1]

A competitor could therefore challenge infringement based on the chemical form used, although infringement would depend on claim construction, product composition, prosecution history, and the full patent record.

What is the Orange Book status of US 8,653,119?

US 8,653,119 is associated with the Vyndaqel patent estate and is relevant to FDA-approved tafamidis meglumine use. The FDA Orange Book identifies patents submitted by NDA holders for approved drug products and approved methods of use.[4]

The most important regulatory distinction is between Vyndaqel and Vyndamax:

Product	Active ingredient or form	Commercial relevance of US 8,653,119
Vyndaqel	Tafamidis meglumine	Directly aligned with the patent’s expressly claimed salt
Vyndamax	Tafamidis free acid	Requires separate analysis of listed patents and claim coverage
Generic tafamidis meglumine	Salt form	Potentially exposed to method-of-use patent claims
Generic tafamidis free acid	Free-acid form	Exposure depends on other patents and the scope of any asserted claim

The Orange Book listing does not itself establish validity or infringement. It provides regulatory notice and determines, in part, the certification framework available to an abbreviated new drug application applicant.

When does US Patent 8,653,119 lose exclusivity?

The patent’s projected expiration is June 7, 2028.[2] That date is separate from regulatory exclusivity.

Patent exclusivity

Patent protection is projected to continue through June 7, 2028, subject to the final USPTO term calculation and any applicable patent-term adjustment or disclaimer.

Orphan-drug exclusivity

The FDA approved Vyndaqel and Vyndamax in March 2019 for cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis.[3] The relevant orphan-drug exclusivity period generally runs for seven years from approval of the applicable orphan indication, potentially extending into 2026.

Orphan exclusivity blocks approval of the same drug for the same disease or condition, subject to statutory exceptions. It does not prevent all possible approvals of a different product or a different indication.

FDA approval exclusivity

The FDA’s regulatory exclusivity period and patent term operate independently. A generic applicant may face a patent barrier after FDA regulatory exclusivity ends if the Orange Book patent remains unexpired.

What Paragraph IV challenges could affect tafamidis?

A generic applicant seeking approval before patent expiration could file an Abbreviated New Drug Application with a Paragraph IV certification against an Orange Book-listed patent. The applicant would assert that the patent is invalid, unenforceable, or not infringed.

For US 8,653,119, likely challenge theories would include:

Non-infringement based on use of tafamidis free acid rather than tafamidis meglumine.
Non-infringement based on a proposed label that omits the claimed disease uses.
Obviousness based on prior transthyretin stabilizer work, known benzoxazole compounds, and known salt-selection practices.
Lack of written description or enablement for the full range of transthyretin amyloid diseases.
Invalidity based on anticipation if an earlier reference disclosed the claimed salt and treatment.
Section 112 or claim-construction challenges directed to “therapeutically effective amount” and “subject in need thereof.”

A Paragraph IV notice letter would ordinarily create a 45-day period for the patent holder to file suit. A timely suit can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action.[5]

No specific publicly verified Paragraph IV litigation or settlement terms should be attributed to this patent without a current review of FDA, PACER, and district-court records.

How strong is the patent estate for tafamidis?

US 8,653,119 is meaningful but narrower than a composition-of-matter patent.

Strengths

It directly covers the N-methyl-D-glucamine salt used in Vyndaqel.
It covers multiple transthyretin amyloid disease categories.
It includes both administration claims and pharmaceutical-composition claims.
It contains narrower species claims for familial amyloid cardiomyopathy and other defined conditions.
The expiration date extends beyond the initial US orphan-drug exclusivity period.

Vulnerabilities

The patent is limited to treatment methods.
It does not broadly claim all tafamidis molecules as a chemical composition.
The claims do not include a specific dose, formulation, or clinical-response requirement.
Salt-selection and method-of-use claims can face obviousness challenges.
A product using tafamidis free acid may present a non-infringement position, depending on other patents.
Generic labeling strategies may narrow or omit patented indications.

The patent’s practical value is highest against a generic tafamidis meglumine product seeking approval for the covered amyloid-cardiomyopathy uses.

What formulation patents protect tafamidis products?

US 8,653,119 is not primarily a formulation patent. Claim 3 requires a pharmaceutical composition containing the salt and a pharmaceutically acceptable carrier, but it does not claim a specific excipient system, capsule shell, dissolution profile, particle size, polymorph, or manufacturing process.

Separate formulation or solid-state patents may protect:

Tafamidis free-acid formulations
Tafamidis meglumine formulations
Capsule compositions
Crystalline forms
Particle-size distributions
Stability improvements
Dissolution characteristics
Manufacturing and salt-formation processes

Those patents must be analyzed separately from US 8,653,119. A formulation patent could create a later-expiring barrier even if the method-of-use patent expires in 2028.

What patent litigation affects tafamidis generic entry?

The central litigation risk is a Hatch-Waxman dispute involving a generic tafamidis product and any Orange Book-listed patent, including US 8,653,119.

The relevant litigation questions are:

Issue	Commercial consequence
Was a Paragraph IV certification filed?	Determines whether early litigation is likely
Did the patent holder sue within 45 days?	Determines whether the 30-month stay may apply
Is the proposed product tafamidis meglumine or free acid?	Affects literal infringement
Does the proposed label include cardiomyopathy treatment?	Affects method-of-use infringement
Are other patents listed?	May extend the practical patent barrier
Was a settlement reached?	May establish an agreed launch date
Was an authorized generic planned?	Affects price erosion and launch economics

A patent can be listed in the Orange Book without producing litigation. Conversely, a generic applicant can face litigation based on multiple patents, making the commercial launch date dependent on the entire patent estate rather than US 8,653,119 alone.

How does tafamidis compare with competing transthyretin drugs?

Tafamidis stabilizes the transthyretin tetramer. Other products act through different mechanisms.

Product	Company	Mechanism	Product type	Competitive position
Vyndaqel/Vyndamax	Pfizer	Transthyretin stabilization	Small molecule	Established cardiomyopathy franchise
Attruby/acoramidis	BridgeBio/Alnylam	Transthyretin stabilization	Small molecule	Direct mechanism competitor
Onpattro/patisiran	Alnylam	TTR mRNA silencing	siRNA	Approved for hereditary TTR polyneuropathy; broader systemic mechanism
Amvuttra/vutrisiran	Alnylam	TTR mRNA silencing	siRNA	Competes in hereditary and wild-type TTR disease
Wainua/eplontersen	Ionis/AstraZeneca	TTR mRNA silencing	Antisense oligonucleotide	Subcutaneous RNA-targeted competitor
Diflunisal	Generic manufacturers	Transthyretin stabilization	Small molecule	Off-label, lower-cost alternative

Stabilizers and gene-silencing products create different patent risks. US 8,653,119 does not cover RNA-silencing therapies, antisense products, or diflunisal.

What revenue is exposed to the patent?

Pfizer’s Vyndaqel family generated approximately $3.3 billion in global revenue in 2023, reflecting the commercial scale of tafamidis products.[6] The United States is a major market because of the approved cardiomyopathy indication, high per-patient pricing, and the aging population affected by wild-type transthyretin amyloidosis.

Revenue exposure to US 8,653,119 depends on:

The share of sales attributable to Vyndaqel rather than Vyndamax
Whether a generic targets tafamidis meglumine
The number and expiration dates of other listed patents
The outcome of any Paragraph IV litigation
Whether an authorized generic launches
Payer substitution and mandatory generic substitution
Competitive uptake of acoramidis and RNA-silencing therapies

A successful generic launch could produce rapid price erosion in the small-molecule tafamidis market. The magnitude would depend on whether the entrant is limited to a narrow label or competes directly with the full cardiomyopathy indication.

What manufacturing and geographic barriers remain?

US 8,653,119 does not claim a manufacturing process. It therefore does not by itself prevent manufacture of tafamidis or tafamidis meglumine outside the scope of its treatment claims.

Manufacturing barriers may arise from separate patents covering:

Synthesis of the benzoxazole core
Salt formation
Crystallization
Purification
Polymorph control
Pharmaceutical-grade specifications
Capsule manufacture
Stability and packaging

Geographic coverage also differs by jurisdiction. A US patent can block or impose liability on US manufacture, importation, sale, or use within the statutory scope, but it does not automatically control sales in Europe, Japan, China, or other countries. Foreign counterparts require separate review of national grants, claim amendments, annuity status, opposition proceedings, and local expiration dates.

What generic launch scenarios exist?

Three principal launch scenarios are plausible.

Launch after patent expiration

A generic company may wait until the patent and all material regulatory barriers expire. This reduces litigation risk but forfeits earlier market entry.

At-risk Paragraph IV launch

A generic applicant may launch after prevailing in litigation, obtaining a covenant not to sue, or accepting the risk of damages if the patent is later upheld.

Carved-out indication launch

A generic applicant may omit patented indications from its labeling under a section viii statement or a permitted label carve-out. The viability of this strategy depends on whether the remaining label induces infringement and whether the FDA-approved non-patented uses are commercially sufficient.

Key Takeaways

US 8,653,119 is a method-of-use patent covering treatment of transthyretin amyloid disease with a pharmaceutically acceptable tafamidis salt.
Claims 2 and 4 specifically identify tafamidis meglumine, the salt used in Vyndaqel.
Claims 5 through 24 cover familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, and cardiac amyloidosis after liver transplantation.
The patent does not broadly claim tafamidis free acid as a composition of matter.
The projected patent expiration is June 7, 2028.
FDA orphan exclusivity for the US cardiomyopathy approval was expected to end before the patent term.
The principal generic strategies are non-infringement based on chemical form, label carve-out, invalidity, or post-expiration entry.
The commercial risk cannot be assessed from US 8,653,119 alone because separate Orange Book-listed, formulation, solid-state, or manufacturing patents may affect launch timing.
The patent is most valuable against a generic tafamidis meglumine product carrying the covered cardiomyopathy indication.

FAQs

Does US Patent 8,653,119 cover Vyndaqel?

Yes. Its claims expressly cover pharmaceutically acceptable salts of tafamidis and specifically the N-methyl-D-glucamine salt used in Vyndaqel, when administered for covered transthyretin amyloid diseases.

Does US Patent 8,653,119 cover Vyndamax?

Not clearly on its face. Vyndamax contains tafamidis free acid, while the patent claims require a pharmaceutically acceptable salt. Other patents may provide protection for Vyndamax.

Can a generic launch tafamidis before June 2028?

Potentially, but an early launch would require a successful patent challenge, a non-infringement position, a label carve-out, a settlement, or another legally effective pathway.

Is tafamidis a biologic subject to biosimilar competition?

No. Tafamidis is a small molecule. Competitors would generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

Does the patent cover treatment of Alzheimer’s disease or non-transthyretin amyloidosis?

No. The asserted claims are directed to transthyretin amyloid disease and specified subtypes. They do not expressly cover Alzheimer’s disease or unrelated amyloid disorders.

References

United States Patent No. 8,653,119. (2014). Methods for treating transthyretin amyloid diseases. United States Patent and Trademark Office.
United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,653,119. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (2019). FDA approves new treatments for heart disease caused by transthyretin-mediated amyloidosis. https://www.fda.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act. https://www.fda.gov/
Pfizer Inc. (2024). 2023 annual report. https://www.pfizer.com/investors/financial-reports-annual-reports

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1587821	⤷ Start Trial	C300516	Netherlands	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	91935	Luxembourg	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	C20120001 00050	Estonia	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	CA 2012 00006	Denmark	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	1290005-6	Sweden	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	12C0008	France	⤷ Start Trial
European Patent Office	1587821	⤷ Start Trial	126 5003-2012	Slovakia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,653,119